Albrem Biopharma and Emery Pharma Announce Strategic Partnership to Advance Protein Target Development
Albrem Biopharma, a pioneering biotech company specializing in cell-free protein synthesis and protein development, and Emery Pharma, a leading contract research organization focused on analytical chemistry and bioanalysis, are pleased to announce a strategic collaboration aimed at accelerating the development of protein therapeutics through their collaborative offering for controlled protein reagents and formulated proteins.
Albrem Biopharma, is at the forefront of scalable, cell-free protein synthesis technologies. Their innovative approach enables rapid protein expression, screening, formulation and controlled production — these technologies, combined with Emery Pharma capabilities for analytical characterization and stability programs, offers critical services to speeding up early-stage drug development and immunochemistry applications.
Emery Pharma brings decades of expertise in analytical method development, validation, stability testing and regulatory bioanalysis. This collaboration uniquely bridges Albrem’s cutting-edge protein development and formulation with Emery Pharma’s analytical and bioanalytical capabilities, creating a seamless pipeline from protein target synthesis to in-depth characterization and GLP/GMP compliant testing.
Dr. Milan Tomic, CEO of Albrem Biopharma, stated:
“We are thrilled to partner with Emery Pharma. This collaboration allows us to pair our rapid cell-free protein synthesis and platforms with world-class analytical and bioanalytical expertise. Our platforms at Albrem are uniquely designed to enable new protein-specific critical protein approaches. Together, we’re creating a globally unique offering that supports drug discovery and testing programs from early research through early- and late-stage regulatory submissions.”
Dr. Ron Najafi, CEO of Emery Pharma, added:
“Our partnership with Albrem Biopharma opens new possibilities for clients looking to rapidly utilize, and test proteins. By combining their high-throughput synthesis with our deep analytical strength and audited GLP/GMP systems, we’re bringing an end-to-end solution to the biotech and pharmaceutical industries that can characterize their products dependably, through licensure. This additional capability can provide critical analytical insights to product development.”
This strategic partnership will serve clients worldwide, offering integrated services tailored for biotech startups, large pharmaceutical companies, and academic collaborators seeking to gain reproducible data in support of their drug product.
About Albrem Biopharma
Albrem Biopharma is an innovator in cell-free protein synthesis and directed screening technologies. The company provides scalable platforms for rapid protein expression and selection, empowering researchers and companies to accelerate the testing and development of novel biologics.
About Emery Pharma
Emery Pharma is a full-service CRO specializing in analytical chemistry, microbiology, and bioanalysis. Known for its regulatory compliance and advanced instrumentation, Emery Pharma supports pharmaceutical and biotechnology companies in method development, validation, stability studies, and risk assessments.
For media inquiries or partnership opportunities, please contact:
bd@albrem.com | info@emerypharma.com
